Alegysal eye drops 0.1% Santen Preventive Controphe allergic (5ml)

Dosage form Bottle x 5ml
Specifications Pemirolast Kali
Ingredient Allergic conjunctivitis, itchy eye

Ingredient

Thành phần cho 5ml

Composition information	Content
Pemirolast Kali	5mg

Uses

Indications

Treatment of allergic conjunctivitis and spring conjunctivitis.

Pharmacokological

Inhibiting effect on experimental allergic conjunctivitis.

Intravenous or localized Pemirolast Potentine has a strong inhibitory effect on the increase in vascular permeability in the conjunctiva due to an allergic reaction in the mouse. It also shows an effect of inhibiting the movement of eosin and neutrophils to the conjunctival tissue in the mouse.

Mechanism of action (inhibiting the release of chemical mediators):

Pemirolast Pot Learning

blood concentration

Research and use 1 day

The highest concentration in plasma (CMAX) and the time to achieve the highest concentration in plasma (TMAX) of Pemirolast Potassium after being used on the spot the Pemirolast Potassium Potassium Potive solution 0.1% or 0.5% at a dose of 2 drops, 4 times a day in 5 healthy adult male volunteers are summarized below. Pemirolast concentration in plasma 35 hours after the last time under the detection limit (1.0ng/ml).

concentration

0.1%

0.5% 1.0

1.0

After 2 drops of Pemirolast Potassium eye solution 0.5% 4 times/day for 7 days in 6 men who volunteered to grow healthy, plasma concentrations were evaluated. The data shows the same tendency between plasma concentrations on day 1 and 7 shows that there is no cumulative drug due to many days. Plasma concentrations 35 hours after the last few days below the discovery (1.0ng/ml).

metabolism and excretion

Research and use 1 day

After 2 drops of small pemirolast eye solution 0.1% or 0.5% 4 times/day in 5 men volunteered to grow healthy, Pemirolast concentration of potassium excreted in multi -urine is determined. The drug concentration detected in urine 24 hours is 52.4 ± 19.6µg on the day of use, and below the detection (1.0ng/ml) the next day.

Research for 1 week

In the study for 1 week, the 0.5% small pemirolast eye solution has been 4 times/day for 7 days for 6 men to volunteer to grow healthy. The excretion of Pemirolast Kali in urine 24 hours is determined on April 1 and 7, showing no special changes. The concentration in the 24 -hour urine sample is 286.0 ± 54.0µg on the last day and 54.5 ± 8.6µg immediately after completing the use of the drug, but under the limit of detecting after 2 days at all volunteers except one person.

Internal distribution (rabbits)

Pemirolast potassium concentration in the corresponding eye tissue includes conjunctiva, cornea and anterior part of the concentration, which is higher than the concentration in the inner tissue of the eye after being used by 50µl of 0.1% small eye solution into the rabbit eye. The concentration of the medication in the cornea and the front part of the concentration is reduced over time except for the conjunctiva in which the concentration is still high enough to have a full pharmacological effect even 24 hours after the drug. The concentration of the drug peaks in the aquatic fluid, iris, the eyelashes after 30 minutes, in the retinal membrane 15 - 30 minutes after small, and then reduces the trace about 8 hours after taking the drug. The concentration of the lens and the excitation is negligible. Small amount of Pemirolast Kali was discovered in plasma 15 minutes after small but decreased below the limit detected 4 hours after use.

Before taking Alegysal eye drops 0.1% Santen Preventive Controphe allergic (5ml)

How to use

eye medication.

When used:

The drops of the eyelids on the eyelids should be wiped immediately. In particular, should not be used in too low, high or arbitrary dosage compared to the time the doctor is specified.

Dosage

Normally, apply 1 drop every time, 2 times/day (morning and evening).

What to do when overdose? Remember to record the list of medications used and prescription of the doctor.

What to do when forgetting a dose? However, if it is almost time for the next dose, it is advisable to skip the forgotten dose. Take care not to use double the prescribed dose.

Side Effects

Notify the doctor with unwanted effects when using the drug.

Before being accepted in Japan, side effects on this drug were reported in 16 of 639 patients (2.50%). The main side effect is lash inflammation in 4 patients (0.63%), eye irritation in 4 patients (0.63%) and conjunctiva in 3 patients (0.47%).

After being accepted, side effects on this drug are reported in 43 of 4,255 patients (1.01%) evaluated while investigating the use of drugs and special surveys (these surveys are based on long -term medication and in patients with spring conjunctivitis) in Japan. The main side effects are eye irritation in 16 patients (0.38%), lash inflammation in 9 patients (0.21%), eyelid itching in 5 patients (0.12%), eye discharge in 5 patients (0.12%) and conjunctival congestion in 5 patients (0.12%).

If there are the following side effects, it is advisable to apply appropriate measures such as stopping the drug.

Warnings

Contraindicated

Do not use Alegysal small eye solution if you have a history of hypersensitivity to any component of the drug.

Be cautious when using

Must ensure aseptic: avoid letting the tip of the vial touches around the eyes.

Patients need to wait at least 10 minutes after the new drug is allowed to wear contact lenses because the lauralkonium chloride preservative can be adsorbed on contact lenses.

Patients must not use contact lenses if the eyes are red.

Do not use Pemirolast to treat eye irritation due to contact lenses. Also be cautious with patients with other eyes.

Be cautious when used for patients with liver failure or renal failure due to no pharmacokinetic data in these patients.

Read the instructions carefully before use. If you need more information, consult your doctor. This drug is only used by a doctor.

The ability to drive and operate machinery

It is unknown whether the drug affects the ability to drive and operate machinery or not. If symptoms such as blurred vision, dizziness, dizziness, after using the drug, do not drive and operate machinery.

Pregnancy

only use this medication for pregnant women or possibly pregnant if the benefits are more than risks that may occur due to medication. The safety of this drug during pregnancy has not been determined.

Breastfeeding period

It is unclear whether the drug is excreted through breast milk or not. However, animal research shows that Pemirolast excreted milk with higher concentrations in plasma concentrations. Be careful when using pemirolast for breastfeeding women.

Special objects

The efficiency and safety of pemirolast small eye form in children under 3 years old have not been confirmed.

There is no information on the relationship between age and the effect of drugs in the elderly.

Drug interaction

Currently, there is no report on the interaction of Alegysal with other drugs.

Should consult your doctor if used simultaneously with other drugs.

Storage

Store at a temperature of 15 - 25 degrees C, in closed packaging.

Leave the medicine out of the reach of children.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.